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1.1 APOPTOSIS AND FIBROGENESIS 
Apoptosis is a form of cell death and is characterized by membrane blebbing, chromatin 
condensation and nuclear fragmentation (Kerr JF, et al., 1972). The fragmentation of the cell into 
the membrane is defined by apoptotic bodies. It is an essential process that plays a critical role in 
tissue homeostasis, embryologic development, immunity and resolution of inflammation. 
The clearance of apoptotic bodies is named efferocytosis and is mediated by professional 
phagocytes, such as macrophages and immature dendritic cells (DC), that are mobile and capable of 
infiltrating a wide variety of tissue (Ablin J, et al., 2005), performing key roles during the 
inflammation and its resolution. 
The recognition of apoptotic cells and their efferocytosis by professional phagocytes leads to 
secretion of anti-inflammatory cytokines, such as TGF-β and IL-10, which inhibit the production of 
inflammatory mediators (Voll RE, et al., 1997; Fadok VA, et al., 1998). The defective clearance of 
the apoptotic cells is associated with many autoimmune and chronic inflammatory disorders, being 
the result of genetic anomalies or the persistent diseases state, and contributes to their the 
establishment and progression (Jang E, et al., 2013). 
The initial event in phagocytosis is the recognition of the target; the successful engulfment requires 
that apoptotic cells must generate two signals: “a find me” signal and an “eat me” signal. 
Generally, the apoptotic cell sensing system recognizes the change of expression of lipids or 
carbohydrates on the outside membrane of dying cells (Greenn D, 2003; Ravichandran KS, and 
Lorenz U, 2007). Indeed, the loss of membrane asymmetry during the apoptosis leads to oxidation 
of phospholipids, that represent an “eat-me” signal, recognized by specific brinding molecules (or 
find me signals) that facilitate the phagocytosis through interaction with the specific receptors 
(Fadok VA. et al.; 1998). 
 Once recognized as “eat me” signal, the phosphatidylserine is traslocated from cell surface 
(Savill J, et al., 2000). The phagocytes recognize this signal and trasduce him to the cell machinery 
required for engulfment. (Henson PM et al., 2001). Finally the ingested particles enter in the 
lysosomal system and are degradated. 
The ingestion of the apoptotic cells results in potent anti inflammmatory and 
immunosuppressive effects, through the production of anti-inflammatory cytokines and the 
suppression of pro-inflammatory mediators release from activated macrophages (Voll RE, et al., 
1997, Fadok VA, et al., 1998; Lemke G, and Rothlin C, 2008). 
The professional phagocytes display several receptors on the membrane that participating in 
the recognition and in the efferocytosis processes. The involved receptors include: scavenger 
receptors class A, CD36 and phosphatidylserine (PS) receptors, molecules belonging to the 
immunoglobulin superfamily, vitronectin receptor, CD14;lipopolysaccharide (LPS) receptor, 
complement receptor and TAM receptors (Platt N, et al., 1996; Taylor PR, et al., 2000). 
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TAM receptors are one of 20 subfamilies of receptor tyrosine kinases (RKTs) that regulate 
different processes including cellular proliferation/survival, cellular adhesion/migration and release 
of the inflammatory cytokines. 
This subfamily of RKTs comprises three receptors, Tyro-3, Axl and MerTK, which share 
the ligands Gas6, TULP1, Tubby and protein S, and mediate several cellular functions, including 
macrophage clearance of the apoptotic cells, platelet aggregation and cellular differentiation of  
natural killer (NK) In particular, MerTK receptors seems to be essential for engulfment and 
efferocytosis (Scott Rona S, et al., 2001). 
The efficient execution of efferocytosis is a key mechanism in maintaining tissue 
homeostasis and also contributes to the initiation of repair processes following an injury (Rigamonti 
E, et al., 2014; Wan E, et al., 2013). 
The recognition of apoptotic cells themselves, by professional phagocytes, can reinforces 
pathways and enhances efferocytic ability through the activation of Peroxisome Proliferator-
Activated Receptor gamma (PPAR-γ), PPAR-δ and Liver X Receptor (LXR) followed by the 
enhanced CD36 and MerTK expression (Gregory CD, et al.; 2004; McColl A, et al.; 2009) and the 
secretion of efferocytic bridge molecules ( A-Gonzalez N, et al., 2009; Mukundan L, et al., 2009; 
Roszer T, et al., 2011). 
PPAR-γ, PPAR-δ and LXR are also up-regulated both during IL-4 signaling (Fernandez-
Boyanapalli RF, et al., 2009), that stimulates TGF-β production, and during the macrophage 
differentiation (Mukundan L, et al.; 2009; Roszer T, et al.; 2011); these events culminate in the 
suppression of the inflammation. 
These observations reinforce the concept of plasticity in macrophage programming, during 
the course of the inflammatory response, with the early induction of protective properties and later 
development of activities that promote the resolution. 
The apoptotic response is associated with liver disease and includes soluble stimuli, 
inflammatory cells, resident parenchymal cell and fibrogenic cells. The cellular apoptosis is the first 
response to toxic events, following a viral hepatitis, alcohol-induced disease and nonalcoholic 
steatohepatitis, and correlates with disease severity and hepatic fibrosis (Natori S, et al., 2001; 
Feldstein AE, et al., 2003). 
In the liver, the hepatic stellate cells (HSCs), the pericytes of the sinusoids and the kupffer 
cells are able to perform efferocytosis (Canbay A, et al., 2003; Jiang JX, et al., 2009) and contribute 
to inflammation through the activation of several mechanisms. First, if apoptosis is activated 
improperly, it leads to accumulation of the apoptotic cells and to generation of soluble mediators 
that elicit the inflammatory response (Patel T, et al., 1998). Alternatively, the apoptosis of the 
hepatocyte induces the production of the chemokines, througha mechanism Fas/Fas-ligand-
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dependent, that promotethe infiltration of the neutrophilsand stimulate the inflammation (Faouzi A, 
et al., 2001). 
A consequence of the hepatic inflammation is the activation of HSCs into a myofibroblast–
like phenotype (Maher JJ, et al., 2001) which directly stimulate fibrogenesis (Fadok VA, et al., 
1998; Platt N, et al., 1998).This transitionis responsible of extracellular matrix production within 
the injured liver(Friedman SL, 1993). 
HSCs express as core machinery to phagocytose the apoptotic bodies the PS receptor, that is 
an “eat me signal” to stimulate the engulfment (Somersan S, et al., 2001). When the HSCs engulfe 
apoptotic bodies, a switch from quiescent cells to myofibroblasts is observed, leading to the 
production of TGF-β (profibrogenic cytokine), and collagen alpha I (the major constituent of 
cirrotic liver) (Canbay A, et al., 2003). To provoke engulfment, apoptotic cells release into the 
extracellular space chemical mediators that serves as chemo-attractant signal to recruit professional 
phagocytes to the site of the dying cell. These chemical mediators may function also to recruit 
HSCs to sites of liver injury and promote their activation (Bourd-Boittin K, et al., 2009). 
Several studies have linked hepatocyte apoptosis and efferocytosis to liver fibrosis 
(Feldestein AE, et al., 2003; Meriden Z, et al., 2010). The hepatocyte apoptosis is generally 
mediated by the extrinsic pathway that involves four death receptors, such as the FAS, the tumor 
necrosis factor receptor 1 (TNF-R1), the death receptor 4 and 5 (DR4 and DR5) and their ligands, 
Fas ligand (FasL) the TNF-α and the TRAIL (Faubion WA, et al., 1999). 
The Fas and TNF-R1activation is associated with hepatocyte apoptosis in a wide variety of 
liver disease, including viral hepatitis, nonalcoholic fatty liver disease (NAFLD) and nonalcoholic 
steatohepatitis (NASH) (Akazawa Y, et al., 2007). After the engulfment, the professional 
phagocytesproducts the death ligands (TNF-α, TRAIL and FasL). In addiction the apoptotic DNA is 
recognized by intracellular Toll-Like Receptor 9 (TLR-9), which activates a variety of signaling, 
leading to the production ofcytokines, the amplification of the inflammatory responseand the 
expression of TAM  receptors on the surface of phagocytes (Luke AJ, et al., 2007). 
HSCs, juxtaposed to the hepatocytes, directly stimulate the fibrogenesis (Caberoy NB, et al., 
2010; Canbay A, et al., 2003; Lauber K, et al., 2003) being located to the engulfment site(Canbay 
A, et al., 2004). In contrast, kupffer cells, the resident macrophages, are located within the sinusoids 
and must to migrate into the liver parenchyma for have access to the apoptotic bodies (Canbay A, et 
al., 2003).  
The HSCs produceand increase the expression of potent pro-fibrogenic cytokines, such as 
TGF-β, and of type I collagen through the MAP/PI-3K pathway (Canbay A, et al., 2003) and are 
functionally involved in the progression of liver fibrosis (Patin E, et al., 2012). 
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1.2  TAM RECEPTORs 
 
The TAM receptors are one of 20 subfamilies of RTKs (Robinson DR, et al., 2000) and 
include three members, Tyro-3, Axl and MerTK. These receptors are characterized by an 
extracellular region containing two immunoglobulin (Ig) related domains, followed by two 
fibronectin type III (FN-III) related repeats, a single transmembrane domain and a cytoplasmic 
tyrosine kinase moiety, followed by a short C-terminal tail containing a few tyrosine residues 
(Fig.1). 
 
Fig. 1. The structure of TAM receptors. 
 
Generally, these receptors exist as monomers on the cytoplasmic membrane and the binding 
of their ligands leads to dimerization and subsequent trans-autophosphorylation of tyrosine residues 
(Hubbard SR, et al., 1998). Once the receptor is activated, the tyrosines phosphorylated provide the 
docking sites for the downstream signaling components (Sasaki T, et al., 2006). 
In many cells, the activation of these RTKs is coupled to the downstream activation such as the 
phosphoinositide 3 kinase (PI3K)/AKT pathway, the ERK1/2 Ras and the MAP kinase signaling 
(Keating AK, et al 2010; Lijnen HR, et al., 2011; Ou WB, et al., 2011) (Fig. 2 A). 
Macrophages, dendritic cells and other sentinel cells of immune system express also 
cytokine receptor signaling systems, e.g. the type I interferon receptor (IFNR), that are directly 
coupled to TAM receptors and codependent on them. In these cells, the TAM-activated PI3K/AKT 
pathway is often dominated by a stronger TAM-activated JAK/STAT inhibitor signaling (Zong C, 
et al., 1996; Rothlin CV, et al., 2007; Lemke G, and Rothlin CV, 2008) (Fig. 2 B). 
The differential TAM activation of PI3K/AKT versus JAK/STAT signaling may be 
important for the different activation of distinctactivities TAM-regulated (Fig.2). 
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Figure 2 -A and -B. TAM receptor signaling pathways. 
 
Growth-arrest specific 6 (Gas6), Protein S, Tubby and Tubby-like protein 1 have been 
identified as ligands for TAM receptors. 
Gas6 is a 75-kDa vitamin K-dependent protein, expressed from endothelial cells (Manfioletti G, et 
al., 1993), vascular smooth muscle cells (Nakano T, et al., 1995) and bone marrow (Avanzi GC, et 
al., 1997). It is barely produced in the liver, but instead in the heart, kidneys and lungs.  
Protein S is a vitamin K-dependent protein, produced by a variety of cells types (e.g. hepatocytes, 
endothelial cells, megakariocytes and osteoblasts) (Maillard C, et al., 1992). It is capable of binding 
Factor Xa (FXa) and FVa, inhibiting directly the coagulation (Heeb MJ, et al., 1993; Heeb MJ, et 
al., 1994). 
Gas6 and protein S show high structural homology with an amino-terminal-γ-carboxyglutamic 
acid (GLA) domain, four epidermal growth factor-like domains and a carboxy-terminal (C-
terminal) region that consists of 2 laminin G repeats (LG1 and LG2) (Fig. 3). 
These ligands bindthe phosphatidylserine of apoptotic cells, with their N-terminal GLA domain, 
and the MerTK of macrophages (or Axl and Tyro 3 on dendritic cells), with their C-terminal region, 
causing the intracellular phosphorilation of the kinase domain (Scott RS, et al., 2001; Todt JC, et 
al.; 2004). 
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Figure 3. The structure of Gas 6 and Protein S ligands. 
 
The TAM receptors through Gas6 amplifiethe activation of pro-inflammatory endothelial cells 
(EC) that leads to the expression of vascular cell adhesion molecule-1 (VCAM-1) and intracellular 
adhesion molecule-1 (ICAM-1). Thereby, TAM receptors support the extravasation of the 
leucocytes, the inflammation and an adhesion of platelets to endothelial cells (Tiwa M, et al., 2008). 
Protein S levels are increased in atherosclerotic vessels. Through the activation of MerTK, the 
protein S inhibits the uptake of low density lipoprotein, by the macrophage scavenger receptor, 
reducing the formation of foam cells (Liao D,et al., 2009). These mechanisms can explain part of 
the recent findings about the SNP mutations in the TAM genes, that are related to the formation of 
atherosclerotic plaques (Hurtado B, et al., 2010; Hurtado B, et al., 2011). 
In contrast, the signaling of TAM receptors can also inhibit the inflammation through multiple 
mechanisms. One of this involved the activation of MerTK that induces the transcription of the anti-
inflammatory suppressor of cytokine signaling protein 1 (SOCS1) and SOCS3, inhibitingthe 
cytokine receptors and the TLR signaling (Rothlin CV, et al., 2007; Sun B, et al., 2010). Another 
important mechanism is the amplification of efferocytosis and the production of IL-10 and TGFβ 
(Vandivier RW, et al., 2006). 
Recently, two new ligands ofTAM receptorshave been described: Tubby which binds specifically 
MerTK and Tubby-like protein 1 (TULP1) which interacts with all three RKTs (Caberoy NB, et al., 
2010). 
Tubby and TULP1 belong to tubby protein family and are bridge molecules that present a N-
terminal region(MerTK- binding domain, MPD), and a C- terminal region (phagocytosis pre- 
binding domain, PPBD) (Carroll et al., 2004). They are able to stimulating macrophage 
phagocytosis through the MerTK activation (Finnemann SC, 2003). 
Mutations in the MerTK gene or, in general, in the TAM genes, that bring to the complete or 
partial impairment of the phagocytosis, promote the accumulation of apoptotic cells and elicit the 
pro-inflammatory immune responses. These events can lead to severe states of cellular degeneration 
and death, suggesting a role of these receptors to regulate the efferocytosis and to maintain the 
tissue and cellular homeostasis (Lu Q, et al., 1999; Lu Q, and Lemke G, 2001). 
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1.3  MACROPHAGE POLARIZATION  
The macrophages are mononuclear phagocytes, derived from monocytes released from bone 
marrow into the circulation, which differentiate intothe tissues. They are recognized as 
heterogeneous cells, since they are critical effectors and regulators of the innate and the adaptative 
immunity, the systemic metabolism, the angiogenesis, the malignancy and the reproduction (Bolego 
C, et al., 2013; Roszer T, et al., 2013; Hume DA, 2008). 
They play an important role in the tissue homeostasis and the lesions: promote the initiation 
and progression of tissue injury and improve also the tissue remodeling in various diseases from 
different etiology (Mantovani A, et al.; 2013; Duffield JS, et al.; 2005). 
The macrophage heterogeneity probably reflects the plasticity and the versatility of these 
cells in response to the exposure to microenvironmental signals. Differential production of 
cytokines is a key feature of polarized macrophages to specific functional programs that are defined 
as M1 or M2. 
In response to microbial products or interferon-γ (IFN-γ) these cells are activated as M1 
macrophages (or classically activated macrophages). M1 cells are characterized by high ability to 
present antigen, to produce pro-inflammatory cytokines (e.g. interleukin-12, IL-12) and Tumor 
necrosis factor (TNF), leading to consequent activation of type I polarized response (Th1) (Fig. 4). 
In contrast, various signals, e.g. IL-4, IL-13, glucorticoids and IL-10, immunoglobulin 
complex/TLR ligands, induce the distinct M2 functions (or alternatively activated macrophages). 
M2 cells are able to activate the inflammatory response adaptive Th2, to scavenge the debris, to 
promote the angiogenesis, the tissue remodeling and the repair (Mantovani A, et al.; 2004; 
Mantovani A, et al., 2002) (Fig. 4). 
 
 
Figure 4. Fuctions of M1 and M2 polarized macrophages. 
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In agreement with an alternative activation program, the M2 macrophages express also high 
levels of scavenger receptor-A (SRA), mannose receptor (MR) (Alalvena et al.; unpublished 
observations) andTAM receptors. These receptors contribute collectively to regulate the 
phagocytosis and MerTK plays a predominant role in M2 cells and in thymic macrophages. Mice 
mutant in Mertk gene were not able to clean efficiently the debris or the apoptotic cells. This 
deficiency is attributed to macrophages as demonstrated in vitro (Scott RS, et al.; 2001). 
MerTK receptor is not homogenously distributed in the macrophage population, but is 
mostly restricted to a subset of M2 macrophages, recently named M2c, that secrete anti-
inflammatory cytokines as IL-10 and TGF-β (Martinez FO, et al.;2008).  
M2c polarization is closely associated with the up-regulation of MerTK and is required to 
obtain the macrophages highly specialized in the efferocytosis. M2c cells are also able to release 
Gas6, that can amplify the secretion of IL-10 in an autocrine manner, via MerTK signaling (Zizzo 
G, et al.; 2013). 
Interestingly, following the engulfment of apoptotic cells, the macrophages activate the 
tolerogenic pathways to prevent immune responses against self antigens (Henson P, and Hume D, 
2006; Taylor PR, et al.; 2005). The tolerance is realized through several mechanisms, including the 
suppression of inflammatory cytokine production and the release of anti-inflammatory cytokines, as 
IL-10 and TGF-β (Fadok VA, et al.;1998; Li M, and Flavell R, 2008). If the phagocytosis or the 
tolerogenic pathways are impaired, the chronic accumulation of free apoptotic material can have 
pathological consequences (Henson P, and Hume D, 2006; O’Shea J, et al.; 2002). In addition, 
TAM receptors, able to suppress the TLR signaling, represent a mechanism by which the 
efferocytosis is coupled to immune tolerance (Lemke G, and Rothlin C, 2008; Rothlin CV, et al., 
2007). 
Recently, it has been investigated the role of the M2 differentiation in regulating the 
inflammation and the fibrogenesis (Smith W, et. al.; 1998; Verreck FA, et al.; 2004; Gordon S, 
2003). The factors that control these processes are still to understand (Gordon S, 2003).  
Zizzo and collegues have performed the first systematic study about the effects ofcytokines 
and growth factors on human macrophagesphenotype, on MerTK expression and on Gas6secretion. 
They found that the levels of MerTK and Gas6 followed the expression pattern of CD16 and 
CD163, molecules identifiable as specific M2c markers (Zizzo G, et al.; 2012). 
In addition, M2 cells show also pro-tumoral functions, by promoting the tumor cell survival, 
proliferation and dissemination (Mantovani A, et al., 2002; Pollard JW, 2004; Talmadge JE, 2007). 
These cells are preferentially localizedin the poorly vascularized regions of tumors (Lewis CE, et 
al.; 2006; Leek RD, 2002) where the environment promotes their metabolic adaptation to hypoxia 
through the activation of hypoxia-inducible factor 1 (HIF-1) and 2 (HIF-2) (Leek RD, 2002). 
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M2 cells, producing also IL-10 and TGF-β, contribute to general suppression of anti-tumour 
activities. Moreover, the cross-talk between the macrophages and the neoplastic cells ensures the 
continuous process ofdeposition and remodelingof extracellular matrix, which facilitates tumor 
growth and invasion of the surrounding tissue.  
Furthermore, the M2 macrophages enhance the tumor initiation andthe metastasis 
progression(Liu C, et al., 2013), while the M1infiltration is associated with the tumor regression 
and a favorable outcome of survival (Cook RS, et al., 2013; Helm O, et al., 2014; Maeda R, et al., 
2014).  
Recentlyhas been demonstrated that the overexpression of MERTK in epithelial cancer cells 
results in increased motility and chemoresistance with a strong gain of function and ability in 
efferocytosis. In the same model, the overexpression of MERTK induces Programmed death-ligand 
1 (PD-L1) and PD-L2 expression, a known blockade of immune checkpoint in cancer, which could 
alter the immune balance for tolerance and progression (Khanh-Quynh N, et al., 2014). 
Since the efferocytosis MERTK-mediated, tends to release factors able to promote tissue 
remodeling and immune system suppression, it is possible that cancer cells adopt “MERTK 
enhanced efferocytosis” as a strategy for the tumor tolerance ((Khanh-Quynh N, et al., 2014). 
1.4  LIVER FIBROSIS  
Liver fibrosis is a main feature of the chronic liver injury and is characterized by the 
conversion of the “normal low-density basement membrane-like matrix” to the “high-density 
interstitial type matrix”, containing fibrils that form collagen. The extensive liver fibrosis derives 
from the deposition and the accumulation of type I collagen and is recognized as cirrhosis (Dan L, 
et al.; 1999). 
Liver fibrosis is reversible, whereas cirrhosis is generally irreversible. The clinical 
complications of cirrhosis include the portal hypertension and the chronic liver failure. 
Normal liver contains epithelial cells (hepatocytes), tissue macrophages (Kupper Cells) 
and perivascular mesenchymal cells (HSCs). HSCs are organized within the sinusoid, with the 
sub-endothelial space of Disse that separates the epithelium from the sinusoidal endothelium. In 
normal liver this space contains a “basement membrane-like matrix” (Fig.5) (Scott L, Friedman, 
200). 
When liver becomes fibrotic, the composition of hepatic ECM is modified, both 
qualitatively and quantitatively. The collagen and non collagenous components increases 3-5 fold, 
accompanied by the shift in the type of ECM in the sub-endothelial space, that becomes an 
“interstitial type matrix containing collagens” (Fig.5) (Scott L. Friedman, 200). 
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Figure 5.Phenotypic features of the sinusoidal endothelium in the normal liver and during 
the liver injury. 
 
The HSCs are the key fibrogenic cells in injured liver and have been identified as 
important effectors in the hepatic inflammation (Bataller R. et al.; 2005). 
Quiescent HSCs are primary cells in the body responsible for the storage of the vitamin A 
(Bataller R, et al., 2004; Bataller R. et al.; 2005). Upon activation by liver injury, the quiescent 
HSCs trans-differentiate into myofibroblasts, which produce inflammatory cytokines and secrete 
collagen types I and III, the main proteinsof the matrix, responsible for the development of liver 
fibrosis and cirrhosis (Friedman S.L. 2000). 
Reactive oxygen species (ROS), EIIIA isoform of fibronectin, produced by endothelial 
cells, and other paracrine stimuli generated from platelets (PDGF, TGF-β and EGF) are implicated 
in the initiation phase of the HSCs activation (Eng and Friedman, 2000). Additionally, during this 
phase, the endothelial cells convert the latent TGF-β to the active fibrogenic form, through the 
activation of plasmin (Friedman S.L. et al.; 1999). 
TGF-β, seems to play a dominant role in fibrogenesis, participating in the multiple phases 
of the HSCs activation (Blobe GC, et al.; 2000; Dooley S, et al.; 2001; George J, et al.; 1999). 
This cytokine is a strong fibrogenic signal (Friedman SL, 2000; Friedman SL, 1999) and induces 
collagen I, a major constituent of the cirrhotic scar (Canbay A, et al.; 2003). 
The hepatocytes also promote the activation of HSCs by producing lipid peroxidesthat 
increase the proliferation of HSCs and the synthesis of the collagen I (Gressner AM, 1995). 
The hepatocytes represent the primary source of the apoptotic bodies, characteristic of the 
liver injury (Rust C. et al., 2000). The apoptotic cells are subsequently cleared not only by 
 16 
 
professional phagocytes but also by HSCs (Platt et al.; 1998). When the HSCs engulfs the 
apoptotic bodies, they are activated and generate directly fibrogenicstimuli. 
After the initiation, the activated HSCs, undergo a series of the phenotypic changes, that 
lead to accumulation of extracellular matrix.  
The perpetuation of HSCs activation involves key phenotypic responses, mediated by the 
cytokines and byECM remodeling (Friedman S.L. et al.; 1999). 
The enhanced cytokine response occurs through multiple mechanisms; among these, increased 
expression of cell membrane receptors and enhanced signaling are specially important (Pinzani M. 
et al.; 1998).In particular,RTKs, which mediate many of the responses of HSCs to cytokines, are 
up-regulated during liver injury (Ankoma-Sey V, et al:, 1998; Ankoma-Sey V, et al:,1998). 
During this phase, the continuous ECM remodeling, underlies all cellular responses that 
characterize the progressive liver injury. The low density subendothelial matrix is progressively 
replaced by a rich in collagen fibril form (Scott L et al.; 2000) which accelerates the activation of  
HSCs. These effects are mediated not only through interaction with the integrins, the classic 
receptors of ECM, but also through binding at least to one RTK. 
The phenotypic response of HSCs, after liver injury, includes: proliferation, contractility, 
activation of the fibrogenesis, chemotaxis, matrix degradation, loss of retinoid, release of 
cytokines and leucocytes chemoattraction.  
The HSCs proliferation is induced by platelet-derivated growth factor (PDGF) and is 
associated with both increased of the autocrine PDGF production and up-regulation of PDGF 
receptor (PDGFR) (Pinzani M, et al.; 1998). The activated PDGFR recruits the signaling molecule 
Ras and actives ETK/mitogen-activated protein kinase pathway (Marra F, et al.; 1997). 
The contractility, property of activated HSCs, is induced by the endothelin-1 (ET-1), which 
is in part derived by an autocrine mechanism and represents an important mechanism for the 
increased of the portal resistance during liver injury (Rochey DC, 1997; Rockey DC, et al.; 1998).  
The fibrogenesis is characterized by ECM production from HSCs and is mediated by the 
TGF-β. This cytokine has an important role in perpetuating rather than in initiating the activation 
of the HSCs (Hellerbrand C, et al.; 1999). 
The chemotaxis, the directed migration of the HSCs activated,increasestheir accumulation 
in the areas damaged.The PDGF and the monocyte chemotactic protein-1 (MCP-1) have been 
identified as the chemoattractants for the HSCs activated but not for those quiescent (Marra F, et 
al.; 1997; Marra F, et al.; 1999). 
The matrix degradation is a result of the change in matrix proteases activity, that leads to 
remodeling of the ECM in liver injury, acceleratingtheHSCs activation. In particular, the HSCs 
are a key source of the matrix metalloproteinase-2 (MMP-2) and the stromelysin/ MMP3. These 
cells activated up-regulate also the tissue inhibitor of metalloproteinase -1 and -2 (TIMP-1 and -2) 
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and inhibit the activity of interstitial collagenases, favoring the scaraccumulation (Arthur MJ, 
1995). 
The loss of retinoid is a feature of the activation of the HSCs, but remains unknown 
whether the loss of the intracellular vitamin A is required to activate the HSCs and whether the 
retinoids might accelerate or prevent the their activation. 
Finally, the cytokines release and the leucocyte chemoattraction are critical for the 
perpetuation of HSCs activation. All features of HSCs activation can be attributed to autocrine 
cytokines (Friedman SL, 1999) and the liver ECM represent an important reservoir of growth 
factors. The HSCs can also amplify the inflammation through the release of chemoattractants for 
neutrophil and monocyte (e.g. MCP-1) (Marra F, etal.; 1998). 
The chronic hepatic inflammation, that leads to fibrosis, occurs in response to a variety of 
insults that include viral hepatitis, alcohol and drugs consumption, non alcoholic steatohepatitis 
and metabolic disease due to overload of iron or copper. The complications of fibrosis and its 
progression includes cirrhosis and HCC. 
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1.4.1 PROGRESSION OF LIVER DISEASE IN CHRONIC HEPATITIS C  
 
 Chronic Hepatitis C (CHC) is the most common cause of chronic liver disease and 
cirrhosis and the most common indication for liver transplantation in the United States (U.S.), 
Australia, and most of Europe (Wasley A, et al., 2000; Alter MJ, et al., 1997; Charlton M, et al. 
2001). The prevalence of CHC is estimated at 3% (World Health Organization. 2000) and only a 
minority of those infected spontaneously clears the virus.  
Most of the HCV infections (70-80%) persist and about 30% of these individuals develop 
chronic liver disease (Micallef JM, et al., 2006) including cirrhosis (Seef LB, 2002) which is a 
prerequisite for hepatocellular carcinoma (HCC) development (Hoofnagle JH, et al., 2002; 
Thomas DL, et al., 2005). Factors related both to virus and to host have been associated with the 
differences in HCV clearance or persistence. 
Current standard of care therapy for CHC is the polyethylene glycol (PEG)ylated 
interferon α and ribavirin (PEG-IFN-α/RBV) (Di Bisceglie, AM, et al., 2002). 
The Hepatitis C Virus (HCV) is an RNA-virus that belongs to Flaviviridaefamily. Its 
genome consists of 10 kb and includes the 5’untranslated region, four structural proteins (core, 
envelope protein 1, E1 and E2) , six nonstructural proteins (NS2, NS3, NS4A, NS4B, NS5A and 
NS5B), and a 3’-untranslated region. This genome is initially translated into one single 
polyprotein and subsequently cleaved into the functional proteins (Moradppour D, et al., 2004). 
The HCV enters into hepatocytes via interactions between the envelope viral proteins (E1 
and E2) and the host cell receptors, such as CD81, scavenger receptor class B1 and the tight 
junction proteins (Liu S, et al., 2009; Pileri P, et al., 1998; Scarselli E, et al., 2002). Whereas HCV 
replicates in the cytoplasm of hepatocytes, it is not directly cytopathic, but he persistent infection 
and the rapid production of virus activates a vigorous T-cell immune response. In particular, the 
destruction of the infected hepatocytes and the viral clearance are mediated by distinct T-cell 
populations (Neurmann-Haefelin C, et al., 2005).  
When CD8+ cells are activated, at first, fail to produce interferon-γ (IFN-γ); so this phase is 
characterized by a small reduction of viremia. Subsequently, the CD8+T cells switched to produce 
IFN γ and, in the same time, the number of CD4+T cells increased and the viremia decreased of 5-
log(Herz K, et al., 2007). 
This evidences suggest that hepatocytes destruction, disease pathogenesis and viral 
clearance are mediated by different effector mechanisms (Herz K, et al., 2007). 
Furthermore the death receptors, apoptosismediators, play a critical role in the liver injury 
associated to HCV. In particular, CD95/CD95L system seems to play the most important 
pathogenic role (Hayashi N, et al., 1999). The up-regulation of CD95 in hepatocytes (Hiramatsu 
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N, et al., 1994), as well as the induction of CD95-L expression in T lymphocytes, (Mita E, et al., 
1994) have been correlated with the severity of the inflammation. 
The hepatocytes destruction and their apoptosis are prominent features of the HCV 
infection. The apoptosis acts together with the immune response to clear host infected cells and 
plays an important role in cells elimination that undergo uncontrolled cellular proliferation and in 
preventing viral replication (Nerz K, et al., 2007).  
In addition to the activation of the inflammatory response, HCV can modulate the 
metabolism of the infected hepatocytes. The mechanism by which virus acts to induce 
derangement of the lipid metabolism involves the core, NS3 and NS5A viral proteins (Lerat H, et 
al., 2002; Perlemuter G, et al., 2002; Moriya K, et al., 1997). These viral proteins are also able to 
modulate the hepatocyte apoptosis favoring  hepatocarcinogenesis (Gong G, et al., 2001; Arima N, 
et al., 2001). 
The core protein is associated with the lipid droplets in the cytoplasm of hepatocyte but it 
is also present in the mitochondria and the nuclei (Moriya K, et al., 1998; Moriya K, et al., 1997) 
and it acts differently depending on the presence or absence of inflammatory condition. 
The core protein activity, under inflammation, contribute to oxidative stress condition that 
alters the scavenger system impairing the elimination of damaged cells (Moriya K, et al., 2001); 
so the amplification of inflammatory response and the progression of chronic disease is observed. 
Alternately, the core protein is able to increase the production of oxidative stress with 
consequent over-production of ROS in absence of the inflammatory conditions (Moriya K, et al., 
2001; Moriya K, et al., 2001). This event results in mitochondrial DNA delection indicating 
genetic damage. 
HCV can also induce liver fibrosis independently from inflammation: it has been 
demonstrated that uptake of HCV by HSC, via specific receptors, could play a role in fibrogenesis 
through the modulation of profibrogenic signaling. 
It was been demonstrated that, in the hepatocytes infected, the induction of ROS by viral 
proteins NS3 and NS5B, up-regulates TGF-β production (Gong G, et al., 2001; Arima N, et al., 
2001). Indeed, these viral proteins interact with the mitochondria and induce lipid accumulation 
and degradation, with consequent compartimentalizationand metabolism derangement, resulting in 
the  production of ROS (De Bleser PJ, et al., 1999). ROS induce TGF-β production (Garcia-
Trevijano ER, et al., 1999) andthe same TGF-β amplifies theirproduction (Moriya K, et al., 2001; 
De Bleser PJ, et al., 1999; Pociask DA, et al., 2004; Scuppan D, et al., 2003). 
TGFβ acts as a potent inducer of ECMaccumulation, activating the quiescent HSCs to 
myofibroblasts (Cassiman D, et al., 2002). These cells up-regulate the synthesis of interstitial 
collagens and down-regulate the MMP (Gressner AM, et al., 2002). 
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In addition, viral proteins stimulate the synthesis of mediators profibrogenic and induce the 
activation of p38, MAPK, JNK, ERK and NF-kappa B pathway (Lin W, etal., 2010).  
In particular, NS5A is involved in PI3K/AKT and β-catenin/WNT activation pathways and 
in the escape from apoptosis through caspase -3 inhibition (Street A, et al., 2005). 
The core protein is able to suppress SOCS-1, a tumor suppressor gene, induce the 
generation of ROS and transactivate MAPK and AP1 pathways. The activation of the MAPK 
pathway, in combination with the oxidative stress, contributes to give an advantage to hepatocytes 
for cell proliferation and hepatocarcinogenesis (Koike K. 2006). 
The core protein inhibits also the immune responses through NF-kappa B activation (Joo 
M, et al., 2005), whereas the activation of JNK pathway generates the inflammatory hepatic 
microenviroment that supports HCC development (Hui L, et al., 2008). 
The viral proteins subvert also the signaling of the innate immune, through the inhibition 
of natural killer cells and the impairment of the antigen-presenting cells (Li XD, et al., 2005; 
Tacke RS, et al., 2011). 
Thus, the core protein and other viral proteins are capable to induce the overproduction of 
oxidative stress in the absence of inflammation and can contribute also to the 
hepatocarcinogenesis during the HCV infection. 
In CHC another source of the over-production of oxidative stress is the hepatic steatosis 
(Moriya K, et al., 2001; Shintani Y, et al., 2004; Koike K, et al., 2005).  
The mechanism of the HCV associated steatosis shares similarities with that involved in 
NAFLD and requires “two hit” for its progression (Day CP. 2002; Day CP, et al.,1998). 
The alteration of the double membrane structure within mitochondria, mediated from core 
protein, causes an impairment of the lipid oxidation and acts as the “first hit” for the development 
of steatosis. Indeed, the core protein, that has as target the microsomal triglyceride transfer protein 
(MTP), interferes with the assembly and the secretion of the apolipoprotein (apo) B, containing 
very low density lipoprotein (VLDL) (Perlemuter G, et al., 2002).More recently, it was been 
shown that the core protein may induces the oxidative stress directly acting on the mitochondrial 
electron transport (Okuda M, et al., 2002). 
The activation of antiviral inflammatory responses represents the “second hit” in CHC for 
the progression from steatosis to fibrosis. (Moriya k, et al., 1998). 
The antiviral inflammatory responses represents a source of free radicals, as well as of pro-
inflammatory and profibrotic cytokines. In support of this, it was been demonstrated that the 
degree of sinusoidal fibrosis, in additional to the steatosis, correlates with the severity of both 
portal and lobular inflammation (Clouston AD, et al., 2001).  
Thus, the induction of oxidative stress, mediated by HCV, and its role in fibrosis, 
represents the major mechanism for the progression of the hepatic disease and for the 
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development of HCC, driven from cirrhosis, in patients with CHC (Yoshida H, et al., 1999; 
Fattovich G, et al., 2004). 
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1.4.2 PROGRESSION OF LIVER DISEASE IN CHRONIC HEPATITIS B 
 
 Chronic infection with hepatitis B virus (HBV) affects about 400 million people and 
is estimated that worldwide over 200,000 and 300,000 chronic HBV carriers die each year 
respectively from cirrhosis and HCC (EASL 2003; Perez JF, et al., 2006). 
 HBV, an encapsulated virus, belongs to hepadnaviridae family and show preferential 
tropism for hepatocytes, where replicates through an RNA intermediate. This virus has a 
circular partially double stranded DNA genome of approximately 3.2 kb pairs (Summers J, et 
al., 1982). 
 The genome contains four open reading frames (ORFs) that cover the entire genome: 
pre-S/S ORF encodes three viral surface proteins; pre-C/C ORF encodes the antigen “e” 
(HBeAg) and the antigen “core” (HBcAg); P ORF encodes the terminal protein (TP) and the 
viral polymerase, that has DNA polymerase, reverse transcriptase and of RNaseH activities. 
The X gene encodes a small protein essential for virus replication. Finally, HBSP is a viral 
protein that is encoded by a spliced viral transcript but its function is unknown (Soussan P, et 
al., 2000). 
 The natural history of chronic infection by virus B (CHB) involves four key phases, 
that are defined based upon the combination of the serum markers (Hadziyannis SJ. 2011). 
When HBV infects host cells, estabilishes an acute infection that can become chronic 
depending on the age and the modes of transmission.  
The acute infection becomes chronic if HBV, that is infecting,  is wild type in precore region 
and is able to produce HBeAg. However the expression of HBe protein requires the host 
immune tolerance against HBV(Cote PJ, et al.,2000; Hadziyannis SJ, et al., 2001). 
Once HBV infection has become chronic, the subsequent course consists of four variable 
duration phases depending on a balance between viral parameters and immune host response 
(Ganem D, et al., 2004). 
The first two phases are associated with HBeAg seropositivity, while the other two are 
characterized by the clearance of HBeAg and the development of anti-HBe immunity (Milich 
DR. 1989; Milich DR. 1991). 
However, a subgroup of patients that undergo seroconversion to anti-HBe antibodies and 
becomes HBeAg-negative, are characterized by periodic reactivation. This event is associated 
with fluctuating levels of alanine aminotransferase (ALT), HBV DNA positivity and an active 
hepatitis with variable fibrosisdegree. By contrast, loss of HBsAg during the second phase is 
associated with a favorable prognosis, although the incidence of HCC remains higher respect to 
not infected population (Paterlini P, et al., 1991). 
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Hepatocytes apoptosis is feature of HBV infection and cytotoxic lymphocytes T (CTLs) 
exert an important role in the pathogenesis of disease. Indeed, CTLs activate simultaneously 
the death receptor CD95 and the perforin pathways, the principal responsible for the killing and 
damagecellular, in absence of HBsAg retention. 
In contrast, the IFNγ pathways are primarily responsible for killing of hepatocytes with 
HBsAg retention independently of presence or absence of CD95 receptor or perforin signaling 
(Herzer K et al., 2007). 
The most of HCC develop in cirrhotic livers, whereas a significant fraction of liver cancers, 
HBV-related, occur in absence of liver cirrhosis. The low rate of cirrhosis can be explained 
with the ability of HBV to integrate into the host genome and to play, potentially, a direct 
carcinogenic activity.  
The integration of viral DNA causes the alteration of human genome, leading to mutations 
of genes implicate in cell proliferation, migration, differentiation and survival (KM; Sze, et al., 
2013;WK, Sung et al., 2012; Y, Tao et al., 2011). Indeed, it was been shown that HCC, induced 
by HBV, displays also higher rates of chromosomal alterations (Marchio A, et al., 2000) and 
implies also a complex interaction between viral and host factors. 
HBsAg is able to compromise hepatocellular function (Chisari FV, et al., 1995) through its 
accumulation in the endoplasmic reticulum (ER) and the formation of hepatocytes to “ground-
glass”(Pasquinelli C, et AL., 1992). 
HBsAg can also play a direct role in HCC development: accumulating in ER, can induce 
oxidative stress, which cause DNA damage and alterations of pathways related to cell death 
mechanisms, survival, proliferation, invasion, and apoptosis(Pasquinelli C, et AL., 1992). 
HBx is a viral protein present at high concentrations in the cytoplasm and at low 
concentrations in the nucleus. At cytoplasmatic level activate apoptosis through localizing in 
mitochondria, or stimulate HBV replication through localizing in the nucleus (Keasler VV, et 
al., 2009). This protein can also induce apoptosis by promoting ROS generation, activating 
caspasi 8 and removing the mitochondrial membrane potential. In addition, HBx induce 
apoptosis up-regulating Fas-Ligand (Fas-L) (RX, Tang, et al., 2012) and interacting with 
Bcl2/CED-9 signaling (X, Geng, et al., 2012). 
The chronic inflammation status plays an important role in HCC development: cycles of 
cellular inflammation, that induce apoptosis, and regeneration of the hepatocytes, increase the 
risk of HCC. Cytokines, such as interleukin 6 (IL-6) TNF-α and TGF-β, play an important role 
in this contest. 
In the early stage of disease, TGF-β promotes cirrhosis progression by accelerating the 
deposition of the extracellular matrix (Matsuzaki K, et al., 2009), whereas, when cancer occurs, 
its persistent up-regulation accelerates the neoplastic growth (Rossmanith W, et al., 2001).
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	 Finally, the epigenetic changes contribute to hepatocarcinogenesis through the interaction of 
the HBx protein with molecular factors that mediate the phosphorylation or the methylation of 
the cellulartargets (E, Khattan, et al., 2012; Y, Huang, et al., 2013). In particular, HBx induce 
hypermethylation of tumor suppression genes and interact with the histone acetyltransferase or 
methyltransferase (Y, Tian, et al., 2013). 
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1.4.3 PROGRESSION OF LIVER DISEASE IN NON ALCOHOLIC FATTY LIVER 
DISEASE  
 Nonalcoholic Fatty Liver Disease (NAFLD) is characterized by excessive accumulation of 
triglyceride within the liver and comprises a large spectrum of disease, including hepatic steatosis 
and non-alcoholic steatohepatitis (NASH), which can progress to the cirrhosis and its 
complications, like the hepatic failure and the HCC (Ong JP, et al., 2007). 
It was been proposed the “two hit hypothesis” to explain the molecular mechanism for the disease 
progression from NAFLD to NASH. According with this hypothesis, the “first hit” is the 
accumulation of lipids into the hepatocytes, that results in the simple steatosis; whereas the “second 
hit” is caused by the oxidative stress and subsequent necro-inflammation, that leads to the NASH 
(Day CP, et al., 1998; Day CP, et al., 1998). However, kupffer cells and HSCs contribute to 
progression from the simple steatosis to the NASH (De Minicis S, et al., 2011). 
 The free fatty acids (FFAs) play a crucial role in the direct promotion of liver injury. Indeed, 
insulin resistance, associated with obesity, metabolic syndrome and diabetes, leads to increased 
release of the FFAs from the adipocytes and their increased influx in the liver, where FFAs undergo 
β-oxidation or are esterified with glycerol to form the triglycerides. The accumulation of 
triglycerides in the hepatocytes increases the oxidative stress that activates the inflammatory 
pathways (Feldestein AE, et al., 2004). Additionally, the oxidative stress inhibits the replication of 
mature hepatocytes, resulting in the inadequate expansion of the hepatic progenitor cell population, 
(Roskams T, et al., 2003) and induces an excessive death of the hepatocytes (Jou J, et al., 2008). 
The cytotoxic products from lipid peroxidation, that impaire the cellular functions of the 
hepatocytes, activate also apoptotic mechanisms that, if on one hand represent an essential process 
to resolvethe inflammation, on the other hand play a role in fibrogenesis by modulating the HSCs 
activation  and collagen expression (Ikejima K, et al., 2007; Ahima RS, et al., 2008). 
 Moreover, NASH has been proposed as a probable cause of the idiopathic or cryptic 
cirrhosis (CC) (Bugianesi E, et al., 2002; Caldwell SH, et al., 1999; Poonawala A, et al., 2000) that 
can progress, although rarelyandslowly, to HCC (Bugianesi E, et al., 2002; Marrero JA, et al., 2002; 
Regimbeau JM, et al., 2004).  
 The exact mechanism that regulates the development of HCC in NASH patients is not clear. 
Obesity and diabetes are the risk factors for the development of NASH and CC and they have been 
implicated in the hepatocarcinogenesis (Bugianesi E. 2007). 
Different factors are implicated in the progression of disease from NASH to the HCC, as the insulin 
resistence, the ROS production, the oxidative stress and the inflammation. 
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The insulin resistence and the resulting hyperinsulinemia up-regulates the production of the nsulin-
like growth factor-1 (IGF-1) that stimulates the growth through cellular proliferation and 
apoptosisinhibition of the hepatocytes (Page JM, et al., 2009). 
ROS production, that is increased in the mitochondria of the steatotic hepatocytes, is implicated in 
the hyperplasia (Bugianesi E, 2007; Yang S, et al., 2000) that generally precedes the tumorigenesis 
for many years (Buginesi E, 2007). 
Cancer developmentis supported by oxidative stress through the induction of  tumorigenic 
mutations e.g. in the gene p53 (Hu W, et al., 2002), and in the patients with NASH can also be 
mediated by increased inflammatory cytokines release and NF-kB activation (Luedde T, et al., 
2007). NF-kB activates a chronic cycle of injury, which goes from cellular death to regeneration, 
and that contributes to hepatocarcinogenesis (Luedde T, et al., 2007). 
Finally, c-Jun amino-terminal kinase 1 (JNK1), activated by TNF-α and ROS, was recently been 
linked to NASH and HCC by increasing of hepatic inflammation and apoptosis (Puri P, et al., 
2008). 
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1.4.4 HEPATOCELLULAR CARCINOMA (HCC) 
 
 Hepatocellular carcinoma (HCC) is the fifth most common cancer in the world and 
the third cause of cancer mortality (Shariff MI, et al., 2009).  
It is related to the inflammation and liver fibrosis status (Seitz HK, et al., 2006) but, 
specifically, the chronic inflammatory state appears to be necessary for its initiation and 
development.  
 Several studies reported that viral chronic infections are the major risk factors for the 
development of liver tumor but other risk factors, including alcoholic cirrhosis (1,7%) (Fattovich 
G, et al., 2004), nonalcoholic steatohepatitis (2,6%) (Ascha MS, et al., 2010) and 
hemochromatosis (Kris VK, et al., 2004) are known. 
The development and progression of HCC is a multistep process. A chronic insult, e.g. 
HCV, HBV or free fatty acids, induces liver injury through ROS production, ER stress, necrosis 
and hepatocytes death. 
In particular, HCV acts through the activation of immune inflammatory response that 
promotes the neoplastic transformation. 
HBV, instead, can integrate into the host genome and promote directly the 
hepatocarcinogenesis through a sustained inflammatory damage, regeneration of hepatocytes, 
alteration of DNA repair mechanisms, direct oncogenic transformation and transactivation of 
several viral oncoproteins as HBx. 
The hepatic response involves the HSCsand macrophages activation: the first, produce 
ECM components and growth factors, while the second promote the migration of endothelial 
cells, angiogenesis and fibrosis. These processes, in the context of inflammation and oxidative 
damage to DNA, favoring the mutations accumulation and epigenetic aberrations in the pre-
neoplastic hepatocytes and in the liver stem cells, promote the development of dysplastic nodules 
and their malignant transformation (Seitz HK, et al., 2006). 
The stromal liver components, such as the angiogenic cells, the endothelial cell, the HSCs, 
the carcinoma-associated fibroblastic cells (CAFs) and the immune cells, contribute to 
development of cancer in several manners: sustaining the proliferative signaling, evading the 
growth suppressors, resisting the cell death, enabling the replicative immortality, inducing the 
angiogenesis, activating the invasion and the metastasis, reprogramming the energy metabolism 
and evading the immune response ( Hanahan D, et al., 2012). 
The angiogenesis plays an important role in early stages of cancer development (Zhu AX, 
et al., 2011): the tumor massgrowth creates an environment deprived of nutrient and oxygen and 
induces the activation and the proliferation of endothelial cells (ECs) to generate new vessels 
from preexisting ones (North S, et al., 2005). 
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The ECs liberate enzymes to disrupt the membrane basement and migrate to their final 
location where they form new vessels together with the ECM. In particular, ECM is involved in 
vessel lumen formation, in tubulogenesis and deposition of a supportive membrane basement 
(Coulon S, et al., 2011). 
The ECM, normally, is essential to support the liver architecture (Lu P, et al., 2012) but, in 
the hepatic disease, the activity of remodeling enzymes is deregulated; this leads to a fibrotic 
microenvironment, characterized by increased of stiffness and by abundance of growth factors 
that contribute to tumorigenesis (Lu P, et al., 2012) and directly affect the epithelial cells with 
consequent cellular transformation and metastasis. 
Inflammation predisposes at the beginning of cancer and several inflammatory mediators 
have been implicated. In particular, the TH2 inflammatory response is associated with HCC 
phenotype more aggressive and metastatic (Budhu A, et al., 2006; Budhu A et al., 2006).  
High levels of IL-6 and IL-22, that are produced by kuppfer cells in response to hepatocyte 
damage, have been detected in tumoral microenvironment. These cytokines lead to tumor 
growth, apoptosis inhibition, and metastasis promotion through the Signal Transducer and 
Activator of Transcription 3 (STAT3) activation (Tilg H, et al., 1992; Jiang R, et al., 2011). IL-6 
exerts also its oncogenic activity by triggering downstream ERK pathways, which controls target 
genes involved in both cell proliferation and survival (Maeda S, et al., 2005). 
The TNF-α is strongly involved in HCC pathogenesis by promoting invasion, angiogenesis 
and metastasis (Lewis CE, et al., 2006) and by activating the phosphorylation of p38, MAPK, 
ERK and by IL-8 production (Wang Y, et al., 2012). TNF-α stimulates also the activation of 
CAFs, dominants cells in tumoral inflammatory environment. 
The IL-10 is the most important immunosuppressive cytokine that, together with TNF-α, 
reduces the CD8+ cells activity and supports the tumor immune escape (Kuang DM, et al., 2009; 
Ke W, et al., 2009). It is also involved in the induction of Forkhead Box P3 (FOXP3+) that 
regulates T cell differentiation. FOXP3+ suppresses the activity of the effector T cells and is 
associated with aggressive HCC (Zhou J, et al., 2009). 
The chemokines are critical in the chemotactic and trafficking cell into and out from the 
tumor microenvironment and have been implicated in immune system evasion, angiogenesis, 
invasion and dissemination (Roussos ET, et al., 2011). 
NF-kB, which plays a key role in HCC development, is activated in epithelial cells and 
macrophages from pro-inflammatory stimuli, such as hepatitis virus (Kim HR, et al., 2010;) and 
free fatty acids (Shi H, et al., 2006). Activated NF-kB induces the growth and the survival of 
malignant hepatocytes through the release of the inflammatory cytokines, such as IL-1α. 
The immune system plays an crucial role in the development of HCC and the tumor- 
associated macrophages (TAMs) are a major component of leukocyte infiltrate. 
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TAMs establish a crosstalk between tumor and stromal cells (Mantovani A, et al., 2011) 
and their recruitment leads to secretion of soluble mediators, which support the tumor cell 
survival,  proliferation and dissemination. 
In the tumoral microenvironment, TAMs are mainly polarized in M2 phenotype and PGE2, 
TGF-β, IL-6 and IL-10 are the factors that promote this polarization (Mantovani A, et al., 2005; 
Chomarat P, et al., 2005). 
In addition these cells produce immunosuppressive cytokines like IL-10 and TGF-β and 
molecules, such as EGF, VEGF, PDGF that directly affect tumor cell proliferation and 
connective tissue dissolution (Lewis CE, et al., 1995). 
The M2polarized macrophage functions, expressed during the development of tumor have 
an important impact on its progression (Mantovani A, et al., 2002). The major regulators of their 
transcriptional programs are NF-kB, STAT-3 and p50, that concur to establish the permissive 
conditions for tumor progression (Sica a, et al., 2007). 
In addition, TAMs up-regulate the expression of CXCL8 receptor and accumulate 
preferentially in the poorly vascularized regions of the tumor. These regions, where the TAMs 
activate the pro-angiogenic program with consequent expression of VEGF through a mechanism 
mediated by HIF are characterized by low oxygen tension (Talks KL, et al., 2000; Pollard JW,  
2004; Knowles HJ, et al., 2007). 
TAMs produce also the enzymes and the inhibitors involved in the extracellular matrix 
digestion, and are able to release several matrix metalloproteases (MMP2, MMP9) and activators 
of MMPs, favoring the tumor invasion. 
Finally, TAMs suppress the adaptative anti-tumor immune responses through the release of 
IL-10, prostaglandins, TGB-β and indoleamine dioxigenase (IDO) metabolites (Mantovani A, et 
al., 2002). In addition, various cytokines, e.g. IL-6 and IL-10, present in tumor environment 
contribute to promotes the differentiation of monocytes into mature macrophages and blocks 
their differentiation into dendritic cells (DC) (Allavena P, et al., 2000).  
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1.5 OUTLINE OF THESIS 	
 Mer tyrosine kinase (MerTK) is a major macrophage receptor involved in the 
clearance of apoptotic cells and is expressed principally in a subpopulation of macrophages 
defined M2. The M2 cells, together with the M1, belong to Tumor Associated Macrophages 
(TAMs) and are one of the most important players in inflammation and cancer, being also a 
major source of cytokines (Mantovani A, et al., 2008). Most of the TAMs that are involved in 
promoting the tumor, angiogenesis and tissue remodeling have a M2 phenotype (Sica A, et al., 
2008). 
 MerTK is encoded from MERTK gene, located on the chromosome 2 and is involved 
mainly in efferocytosis, but can also stimulate the fibrogenesis acting directly on the 
HSCs(Fadok VA, et al., 1998; Platt N, et al., 1998). 
Genome wide Association (GWA) study reported that the single nucleotide polymorphism 
(SNP) of MERTK (rs4374383) is associated with the risk of developing fibrosis in patients with 
CHC(Patin E. et al., 2012). It seems that the state polymorphic of the MERTK gene (rs4374383 
G> A) may play a key role not only in the control of apoptosis, in the epithelial-mesenchymal 
transition of the HSCs and in the immune response, but also in the mechanisms involved in 
fibrosis progression  and carcinogenesis. 
On the basis of this results, we investigated if the MERTK gene and the variant rs4374383 
(G> A) can influence the risk of progression of the liver disease, in patients with chronic 
infection from the hepatitis viruses (C and B) or with nonalcoholic steatohepatitis (NASH). 
Specifically, in chapter 2, we evaluated if the rs4374383 SNP influences the risk of liver 
decompensation (LD) and HCC in patients with HCV cirrhosis,treated with Peg-interferon alfa-
2b and ribavirin. 
 In chapter 3 we assessed the potential association between the rs 4374383 SNP in 
the MERTK gene and the risk of the development of HCC in a cohort of HBV patients with 
active HBV replication and in a sub cohort of them who achieved a virological suppression on 
long term NUCs treatment. 
 Finally, in chapter 4, we evaluated if thers4374383 SNP of the MERTK gene was 
associated with the severity of liver fibrosis and histological features in two combined cohorts of 
533 patients with NAFLD. We also investigated if the MERTK gene is expressed in human HSC 
and in murine models of fibrogenesis. 
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          CHAPTER 2  
A rs4374383 Single Nucleotide Polymorphisms of MERTK gene is linked 
to a higher likelihood of hepatocellular carcinoma in patients with HCV 
cirrhosis 
 
  
 32 
 
 
 
 
 
 
 
 33 
 
 
 
 
 
          CHAPTER 3 
The risk of hepatocellular carcinoma in HBV cirrhosis is affected by 
polymorphisms of the MERTK gene 
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          CHAPTER 4 
MERTK rs4374383 polymorphism affect the severity of fibrosis in 
nonalcoholic fatty liver disease 
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5. SUMMARY AND GENERAL DISCUSSION 
 
In chapter 2, we evaluated a prospective cohort of 349 patients with compensated HCV 
cirrhosis, treated with Peg-Interferon alfa-2b and ribavirin. 
Among 349 patients, the AA rs4374383 genotype was reported in 16.9%, the GA genotype 
in 46.4% and the GG genotype in 36.9%. Of whole cohort, only 87 patients achieved a Sustained 
Virological Response (SVR).During follow-up, 6.8% of the patients with SVR and 25.2% of 
those without SVR developed HCC. 
 The variables independently associated to development of HCC were the age (HR:1.04), the 
absence of SVR (HR:3.31) and the genotype AA of rs4374383 SNP (HR:2.67) (Tab. 1). 
 
 
Table 1. Risk factors for HCC by Cox multivariate model. 
 
 By evaluating the incidence of HCC, according to SVR and genotypes of rs4374383 SNP, 
we have been found that the risk of developing HCC was higher in the patients with HCV 
cirrhosis, non responders to antiviral therapy and carrying genotype AA compared with whose 
without SVR and with genotype GG or GA (Fig. 6). 
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Figure 6. Incidence of HCC in HCV cirrhosis according to SVR and genotypes of the SNP 
rs4374383 in the MERTk gene. 
 
This study showed that the AA genotype of MERTK if on one the hand confers a low risk of 
developing fibrosis, on the other is associated with a high risk of HCC development. 
 MerTK receptor is a regulator of tumor-associated macrophages (TAMs)involved not only 
in efferocytosis but also in the progression of cancer (Mantovani a., et al., 2011).To comprise if 
the association between MERTK polymorphism and HCC development was virus-dependent or 
was related to the inflammatory response and to mechanisms of angiogenesis or tumorigenesis, 
we studied patients with chronic liver disease from etiology other than HCV infection. 
For this purpose, in chapter 3, we evaluated MERTK polymorphism in a cohort of 554 patients 
with chronic HBV infection, at first presentation. The DNA of only 327 patients was available 
for genotyping. 
Among 327 HBV patients, 169 presented a chronic hepatitis (CHB), 133 were cirrhotic whereas 
the remaining 25 showed HCC. 
The distribution of the rs4374383 genotypesamong the 302 patients without HCC was 
respectively: 14.8% AA genotype, 44.4% AG genotype and 40.8% GG genotype.In the 25 
patients with HCC at baseline, 3 (12%) were GG and 22 (88%) were GA or AA.  
Between the 327 patients, only 248 were given long term treatment with NUCs; among 
these, during follow-up, 30 (26.7% and 73.3% respectively with GG and with GA/AA genotype) 
developed HCC whereas the remaining 218 (46.3% and 53.7% respectively with GG and 
GA/AA genotype) not developed the cancer. 
By evaluating the incidence of HCC, in according to the disease stage and the genotypes of 
rs4374383 SNP, the probability of HCC development is higher in the patients with LC and 
genotypeAA/GA respect to patients with LC and genotype GG. 
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In addition, the incidence of HCC development in CHB patients without cirrhosis and with 
GA/AA or GG genotype respectively was lower and similar respect to those with cirrhosis (Fig. 
7). 
 
Figure 7: Incidence of HCC in patients with chronic HBV infection, according to disease stage and 
genotypes of the SNP rs4374383 in the gene MERTK. 
Thus, the A allele, in homoor in eterozygosity, confers a significant additional risk for HCC 
developing in patients with chronic HBV infection, especially in presence of cirrhosis. 
These results confirm that the association between MERTK polymorphism and HCC is 
virus-independent and correlates with the inflammatory response and probably with the 
mechanisms of angiogenesis and tumorigenesis. 
In addition, we have been found that, if on one hand, AA/GA genotype of rs4374383 SNP, 
is protective respect tofibrosis progression(Patin et al., 2012), on the other the A allele alone 
confers a significant additional risk for HCC. 
 Since the inflammatory status is a feature of chronic liver disease and of its complications, 
in chapter 4,we investigated about the possible influence of MERTK gene polymorphism on the 
progression of fibrosis and its complicationsin two combined cohorts of 533 patients with 
NAFLD.  In addition, in one subgroup  of NAFLD we investigated the MERTK liver expression 
and in murine models of fibrogenesis the MERTK expression in human HSC. 
Among 533 patients,who were been underwent liver biopsy for suspected NASH without 
severe obesity, 37.6% presented GG genotype, 47.8% GA genotype and 14.6% AA genotype. 
A significant fibrosis was observed only in 19.2 % of patients with AA genotype respect to 
30.3% of those which presented GG or GA genotype. The AA genotype was associated also with 
clinically significant fibrosis and histological features of NASH (Table 2). 
About the severe fibrosis (F3-F4) as histological outcome, the AA genotype was associated 
with a lower prevalence of F3-F4 fibrosis and NASH. 
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The prevalence of NASH was not affected by MERTK genotype: indeed, NASH was 
observed in 39.7% of patients with AA genotype and in 44.2% of those with GG or GA 
genotype (Table 2). 
Severe steatosis was observed in 7.7% of patients with AA genotype against the 21% of 
those with GG or GA genotype (Table 2). This result suggests that, in NAFLD, the AA genotype 
can represent a moderator of the effect of the other risk factors (e.g. immune response, apoptosis 
and hereditability such as PNPLA3 rs738409 C>G gene ) that influence the severity of steatosis 
(Petta S, et al., 2015). 
 
 
Table 2. Baseline demographic, laboratory, metabolic and histological features of Italian 
patients, according to MERTK genotype. 
The hepatic expression of MERTK, was evaluated in 94 morbid obese consecutive patients 
from Northern Italy.Among these, 13.8%, characterized by very low prevalence of F2-F4 
fibrosis, showed the protective AA genotype which was associated with lower MERTK 
expression levels (Petta S, et al., 2015) (Fig. 8). 
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Figure 8.Prevalence of F2-F4 fibrosis and MERTK expression levels in relationship with 
the genotype MERTK in 94 morbid obese patients from Northern Italy. 
 
Similarly, in 80 NAFLD patients from the Southern Italian cohort, 15% of subject carrying 
AA genotype, showedlower MERTK expression associated to very low prevalence of F2-F4 
fibrosis, compared with all the others (Petta S, et al., 2015) (Fig.9). 
 
 
Figure 9.Prevalence of F2-F4 fibrosis and MERTK expression levels in relationship with 
the genotype MERTK in 80 NAFLD patients from Southern Italian cohort. 
 
Finally, to establish a possible link between MERTK expression and fibrogenesis in 
NAFLD, the hepatic MERTK expression was assessed in function of fibrosis severity in 27 
patients from the FLIP cohort and in the same Southern Italian cohort of 80 patients NAFLD. 
In both FLIP and Southern Italian cohorts, the patients with F3-F4 fibrosis showed 
significantly higher MERTK mRNA levelsthan those with F0-F1 (Fig. 10 and 11). 
 
 
Figure 10. Relationship between MERTK expression and fibrogenesis in 27 patients from 
FLIP cohort. 
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Figure 11. Relationship between MERTK expression and fibrogenesis in 80 NAFLD 
patients from Southern Italian cohort. 
 
We also investigated the expression of MERTK in two murine models of fibrogenesis. 
In the first model, after a 6-week administration of CCl4, the hepatic expression of MERTK 
was more 6-fold higher than in control mice (Fig.12). 
 
 
Figure 12.MERTK mRNA levels in a well-established model of fibrogenesis in mouse after 
administration of CCl4. 
 
Similarly, in the second model, after a 8-week administration of a MCD diet, the hepatic 
expression of MERTK increased 2.5-fold (Fig. 13). 
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Figure 13.MERTK mRNA levels in a well-established model of fibrogenesis in mouse after 
administration of a MCD diet. 
 
The high degree of MERTK expression in these murine models provide additional support 
to the profibrogenic role of MERTK in a context where are involved metabolic and 
inflammatory pathways (Petta S, et al., 2015). 
In addition to these results, we analyzed if the MERTK mRNA expression was followed by 
its production, in terms of protein, and if MerTK was able to modify the fibrogenic phenotype of 
these cells. The immune-precipitation of the lysates of the HSC with anti-MERTK antibodies 
and blotting for MERTK, revealed a clear band of the expected molecular weight, which was not 
present when lysates were incubated with control antibodies (Fig. 14). 
 
 
Figure 14. Activation of MERTK in cultured human HSC. 
 
To comprise the effect of this activation, we exposed human HSCs, activated by culture on 
plastic, to Gas6. This exposure induced a rapid increase of the activation of ERK1/2 (Fig. 15). 
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Figure 14. Exposure of human HSC at Gas6 and induction of the increase of the activation, 
of ERK1/2. 
 
The Exposure to Gas6 resulted also in an increase in cell migration indicating that, culture-
activated HSC, express functional MERTK(Fig. 15). 
 
Figure 15. The increase of the cell migration after exposure to Gas6. 
 
We next evaluated the specificity of effects of Gas6 using UNC569, a specific small 
molecule inhibitor of MERTK. In HSCs, co-treated with UNC5669, the induction of cell 
migration that we had obtained in response to Gas6 was reverted (Fig. 16A). 
 
Figure 16A. Induction of cell migration in response to Gas6 (dark columns) and reversion 
in HSC co-treated with UNC569 (light columns). 
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The exposure of HSCs to UNC569 resulted also in a significant decreasing in cell viability, 
indicating that MERTK is involved also in the maintenance of survival of the fibrogenic cells 
(Fig.17B). 
 
Figure 17B. Exposure of HSC to UNC569 and significant decrease in cell viability. 
 
To exclude that the effects of UNC569 were due to a non-specific inhibition of other 
molecules, we silenced MERTK using specific siRNA. Also with this approach, the viability of 
HSCs was significantly reduced, replicating the effects of UNC569 (Fig.17C). 
 
Figure 17C. Silencing of MERTK using specific siRNAs and reduction of HSC viability. 
 
To establish if the reduction of cell viability was due to the program of cell death, HSCs 
were exposed to increasing concentrations of UNC569. The treatment with UNC569 resulted in 
the cleavage of PARP and the generation of active caspase-3, compatible with the induction of 
the apoptosis of HSC. Similar result was obtained in Huh-7 cells, used as a positive control, 
treated with doxorubicin (Fig. 17D). 
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Figure 17D. Cleavage of PARP and generation of active caspase-3 after exposure of HSC 
and Huh-7 cells respectively to UNC569 and doxorubicin. 
 
Finally, to investigate about the profibrogenic role of MERTK, HSC were stimulated with 
Gas6 and were assayed for gene expression of procollagen I, in presence or absence of UNC569. 
Gas6, slightly but significantly, increased the expression of procollagen I. These effects 
were inhibited when HSCs were co-exposed to UNC569 indicating that the effects of Gas6 are 
mediated by MERTK (Fig. 17E). 
 
Figure 17E. Procollagen I gene expression in presence or absence of UNC569. 
 
It is clear from these results the crucial role played from MERTK in influencing the 
development of fibrosisand the progression of chronic liver disease (Petta S, et al., 2015). 
The results obtained from the murine models, showed that MerTK is expressed in human 
HSC and acts directly on this cells by inducing the their activation, by supporting the their 
survival, by increasing their migration and by inducing the expression of profibrogenic genes, 
such as procollagene I gene (Petta S, et al., 2015). 
In addition, we found that the AA genotypes of MERTK, associated with lower MERTK 
hepatic expression, is protective against F2-F4 fibrosis in patients NAFLD and is able to 
condition the progression of this chronic liver disease(Petta S, et al., 2015). 
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In contrast, the GG genotype has been associated with the fibrotic phenotype in NAFLD, 
showing a potential direct profibrogenic action. 
MerTK is one of the three RTKs of TAM family, is expressed predominantly in M2 cells 
and acts inhibiting the inflammatory responses and controlling the tissue tolerance (Rothlin CV, 
et al., 2007; Beherens DK, et al., 2003). In particular, MerTK plays a functional role in the 
clearance of apoptotic cells and this function is restricted to a subset of M2 macrophages, named 
M2c, that are characterized by secretion of IL-10 and up-regulation of MerTK. In addition, the 
M2 differentiation is a key process that regulates inflammation and fibrosis (Smith W, et al., 
1998). In chronic disease such as NAFLD, these macrophages play a crucial role to promote the 
HSCs differentiation in the myofibroblastic phenotype and the fibrogenesis, through MerTK. 
Gas6, together with the other ligands, binds MerTK and induces its dimerization and 
autophosphorylation, activating the downstream signaling (Linger RM, et al., 2008; Braunger J, 
et al., 1997). Several pathways including PI3-kinase/AKT/Bcl2(survival) and ERK 
(proliferation). In addition, MerTK suppresses TLR signaling and down-regulates the production 
of pro-inflammatory cytokines through the phosphorylation of STAT1 that promotes the 
induction of SOCS-1 and SOCS-3. (Rothlin CV, et al., 2007; Linger RM, et al., 2008). 
Normally, MerTK releases factors involved in tissue remodeling, immune 
responsesuppression and in tumor-promoting(Mantovani A, et al., 2002; Pollard JW, et al., 
2004). 
However how MerTK is able to conditioning the progression of liver disease remain 
unknown. 
The rs4374383 SNP of MERTK gene is an intronic mutation, that usually creates an 
alternative splicing site responsible ofthe production of an alternative mature mRNAthat can lead 
to a splicing variant loss or gain of fuction.  
Indeed, the results of this genetic study are not able to givefinal information about the 
functional mechanism that links MERTK and progression of liver disease especially in 
neoplastic direction. However, from clinical perspective, it gives a strong suggestion to usethe 
rs4374383 SNP of MERTK as a genetic biomarker useful to identify the patients with high risk 
of chronic liver disease progression in order to carry out a more stringent monitoring. 
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